Bioequivalence and Bioavailability Forum 12:32 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Question:Using Phoenix WinNonlin Crossover object for Tmax test [Nonparametrics]

posted by 0521 - China, 2018-11-09 07:02  - Posting: # 19550
Views: 248

Dear Helmut Schütz,



When using Phoenix WinNonlin Crossover object for Tmax testing, how can I judge whether it is equivalent by the result?:confused:

I read the "The Use Of Non-Parametric Methods In The Statistical Analysis" document(PMID: 4556704), and I think he is doing the following steps to judge:

1. Determine if the P value of the sequence is greater than 0.05,
2. If the P value of the sequence is less than 0.05, the test of "Treatment" cannot be performed.
3. If the P value of the sequence is greater than 0.05, it is judged whether the P value of the treatment is greater than 0.05.
4. If the P value of the Treatment is greater than the equivalent, otherwise it is not equivalent.

5. If the P value of the sequence and the P value of the Period are both greater than 0.05, a sign test can be used instead of the rank sum test used in the above steps.

Assuming α = 0.05, all of the above P values are the results in the "Effects" table.

Is the above judgment process correct?:confused:
If not, what is the correct judgment process?:confused:

PARAMETER Test T_stat L_stat p_Value
Tmax Sequence 177.5 0.91791649
Tmax Treatment|(SEQ1=SEQ2) 220 0.021731156
Tmax Period|(SEQ1=SEQ2) 185 0.62428829
Tmax Treatment & Residual (simultaneous) 5.6567621 0.059108471
[image]

Best,

0521

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,881 posts in 4,026 threads, 1,271 registered users;
online 29 (1 registered, 28 guests [including 17 identified bots]).

Being ignorant is not so much a shame,
as being unwilling to learn.    Benjamin Franklin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed